Walleye Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Walleye Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$270K	Sell	12,900 -500	-4%	-$11.3K	﹤0.01%	3135
2025 Q4	$308K	Sell	13,400 -14,400	-52%	-$474K	﹤0.01%	3296
2025 Q3	$836K	Buy	27,800 +17,800	+178%	+$534K	﹤0.01%	2232
2025 Q2	$364K	Buy	+10,000	New	+$361K	﹤0.01%	2915
2025 Q1	–	Sell	-8,700	Closed	-$366K	–	4984
2024 Q4	$366K	Hold	8,700	–	–	﹤0.01%	3252
2024 Q3	$483K	Hold	8,700	–	–	﹤0.01%	3323
2024 Q2	$358K	Buy	+8,700	New	+$371K	﹤0.01%	3820
2024 Q1	–	Sell	-6,300	Closed	-$301K	–	5813
2023 Q4	$301K	Sell	6,300 -100	-2%	-$3.88K	﹤0.01%	3367
2023 Q3	$228K	Buy	+6,400	New	+$254K	﹤0.01%	3450
2023 Q2	–	Sell	-800	Closed	-$32.1K	–	4796
2023 Q1	$32.1K	Sell	800 -1,000	-56%	-$42.9K	﹤0.01%	3295
2022 Q4	$83.4K	Buy	1,800 +900	+100%	+$35.4K	﹤0.01%	2414
2022 Q3	$37K	Buy	+900	New	+$46.3K	﹤0.01%	2650

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Walleye Capital's RARE Position: Q1 2026 in Review

Walleye Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 228% in Q1 2026, buying an estimated $1.87M and bringing the position to 119,705 shares worth $2.51M. The position accounts for 0.01% of the portfolio, ranked #1288.

Walleye Capital first reported a position in RARE in Q4 2022 and has held it in 14 quarters since. The position peaked at $16.1M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Walleye Capital held 119,705 shares of Ultragenyx Pharmaceutical worth $2.51M as of Q1 2026.
Walleye Capital bought 83,221 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.87M.
Ultragenyx Pharmaceutical made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1288 holding.
Walleye Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 14 quarters since.
Walleye Capital's Ultragenyx Pharmaceutical position peaked at $16.1M in Q2 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.